Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 94

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 94
---
 financial information (the “Summary Pro Forma Information”) presents the combination of the financial information of Iris and Liminatus after giving effect to the transactions contemplated by the Business Combination Agreement, including the Business Combination, and related adjustments further described in the section entitled “ Unaudited Pro Forma Condensed Combined Financial Information. ”

| ​                                                                                                                       
 ​                                                                                                                       
 Summary Unaudited Pro Forma Condensed Combined Statement ofOperations Data For The Nine Months Ended September 30, 2024 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Pro FormaCombined(Assuming NoAdditionalRedemptions) 
 (in thousands, except share and per share data)     
 ​                                                   | ​ |          ​ | ​ | ​ 
 ​ | ​ 
 ​ | Pro FormaCombined(AssumingMaximumRedemptions) 
 ​                                             | ​ |          ​ | ​ | ​ 
 ​ 
 ​ |
|:------------------------------------------------------------------------------------------------------------------------|:--|:--|:----------------------------------------------------|:--|-----------:|:--|:--|:--|:----------------------------------------------|:--|-----------:|:--|:--|
| Operating expenses                                                                                                      | ​ | ​ | ​                                                   | ​ |      5,547 | ​ | ​ | ​ | ​                                             | ​ |      5,547 | ​ | ​ |
| Loss from operations                                                                                                    | ​ | ​ | ​                                                   | ​ |     -5,547 | ​ | ​ | ​ | ​                                             | ​ |     -5,547 | ​ | ​ |
| Net loss                                                                                                                | ​ | ​ | ​                                                   | ​ |     -5,451 | ​ | ​ | ​ | ​                                             | ​ |     -5,451 | ​ | ​ |
| Basic and diluted net loss per share                                                                                    | ​ | ​ | ​                                                   | $ |      -0.20 | ​ | ​ | ​ | ​                                             | $ |      -0.20 | ​ | ​ |
| Basic and diluted weighted average shares outstanding                                                                   | ​ | ​ | ​                                                   | ​ | 26,774,477 | ​ | ​ | ​ | ​                                             | ​ | 26,600,000 | ​ | ​ |
| Summary Unaudited Pro Forma Condensed Combined Statement of Operations Data For The Year Ended December 31, 2023        | ​ | ​ | ​                                                   | ​ |          ​ | ​ | ​ | ​ | ​                                             | ​ |          ​ | ​ | ​ |